Results 61 to 70 of about 5,542 (243)

A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product

Rheumatology and Therapy
Introduction Biosimilars need to demonstrate similarity in terms of quality, pharmacokinetics (PK), efficacy, safety, and immunogenicity. Here, we report the outcome of a comprehensive evaluation of the immunogenicity of the biosimilar BAT1806 compared ...
Hans C. Ebbers, Peter C. Taylor, Xiaomei Leng, Wei Wei, Niamh M. Kinsella, Yinbo Zhou, Xiaolei Yang, Paul Chamberlain   +7 more
doaj   +1 more source

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network

Clinical Pharmacology &Therapeutics, EarlyView.
ASCPT has a mission to advance clinical pharmacology and translational sciences to reduce health disparities. The development, regulatory, and outcomes (DRO) network within ASCPT strives to advance pharmacoequity globally. Pharmacoequity, coined by Utibe Essien (2021), is the principle that all individuals, regardless of race, ethnicity, geography, or ...
Priya Jayachandran, Mayur K. Ladumor, Georgios Vlasakakis, Andrew Riselli, Katarina V. Ilic, Rob C. van Wijk, Mohamed Elmeliegy, Jatinder Kaur Mukker, Aarti Sawant‐Basak, Tao Long, Juyao Dong, Noha Rayad, Tao Zhang, on behalf of the DRO Network   +13 more
wiley   +1 more source

A bibliometric analysis of the global research on biosimilars

Journal of Pharmaceutical Policy and Practice, 2018
Background Biosimilars could be a promising option to help decrease healthcare costs and expand access to treatment. There is no previous evidence of a global bibliometric analysis on biosimilars. Therefore, we aimed to assess the quantity and quality of
Akram Hernández-Vásquez, Christoper A. Alarcon-Ruiz, Guido Bendezu-Quispe, Daniel Comandé, Diego Rosselli   +4 more
doaj   +1 more source

Health technology assessment of biosimilars worldwide: a scoping review

Health Research Policy and Systems, 2020
Background Health technology assessment (HTA) should provide an assessment of a technology’s effects on health and of the related social, economic, organisational and ethical issues. HTA reports on biosimilars can specifically assess their immunogenicity,
Bruna de Oliveira Ascef, Ana Carolina de Freitas Lopes, Patrícia Coelho de Soárez   +2 more
doaj   +1 more source

Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia

BMC Rheumatology, 2022
Background Drug coverage policies that incentivize switching patients from originator to biosimilar products may result in significant health care savings. Our study aimed to detect early impacts on health services utilization following a mandated switch
Anat Fisher, Jason D. Kim, Greg Carney, Colin Dormuth   +3 more
doaj   +1 more source

Advancing Pharmacometrics in Africa: Insights and Perspectives From the 2025 Pharmacometrics Africa Conference

Clinical Pharmacology &Therapeutics, EarlyView.
Pharmacometrics (PMX) in Africa has transitioned from foundational capacity‐building to job creation, scientific leadership, regulatory influence, and health innovation. To accelerate this progress, the 2025 Pharmacometrics Africa Conference (PMXAC‐2025) convened key stakeholders to consolidate the continental PMX community, review progress in local ...
Babatunde Ayodeji Adeagbo, Innocent Gerald Asiimwe, Linda Chaba, Aida N. Kawuma, Francis Williams Ojara, Ochuko Maureen Orherhe, Simon Peter Asiimwe, Veshni Pillay‐Fuentes Lorente, Sharon Sawe, Cassius M. Phogole, Catriona Waitt, Samer Mouksassi, Goonaseelan (Colin) Pillai   +12 more
wiley   +1 more source

Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?

Neurology and Therapy, 2019
Multiple sclerosis (MS) more than any other neurological disorder has experienced a tremendous progress in available evidence-based innovator disease modifying therapies (DMT).
Victor M. Rivera
doaj   +1 more source

Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions

BMC Rheumatology, 2022
Background Biologic and targeted synthetic disease modifying agents (b/tsDMARDs) have broadened the treatment landscape for autoimmune diseases particularly in patients refractory to conventional DMARDs. More recently, the introduction of biosimilars has
Thomas Khoo, Navkiran Sidhu, Franca Marine, Susan Lester, Alannah Quinlivan, Debra Rowett, Rachelle Buchbinder, Catherine L. Hill   +7 more
doaj   +1 more source

Detection of a Distinct Erythropoietin (EPO) Profile After Isoelectric Focusing in Patients With Familial Erythrocytosis

Drug Testing and Analysis, EarlyView.
A basic EPO IEF profile was identified in patients with familial erythropoiesis linked to mutations in noncoding parts of EPO gene. Comparison of blood and urine EPO profiles from these patients differed from adult wild‐type EPO (WT) and from Eprex‐administered patients. Patients' EPO do not differ from WT EPO after analysis using SDS‐PAGE/SAR‐PAGE. It
Laurent Martin, Salam Idriss, Nada Maaziz, Soizic Huerre, Lamine Redouane Mekacher, Kahina Lahmek, François Girodon, Betty Gardie, Magnus Ericsson, Alexandre Marchand   +9 more
wiley   +1 more source

Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data

BMC Rheumatology
Background Safety remains a significant concern for biologic drugs, and studies are needed to ensure a comparable safety profile for biosimilars and their legacy treatments.
Marina G. Birck, Luck Lukusa, Denis Choquette, Gilles Boire, Walter P. Maksymowych, Harminder Singh, Waqqas Afif, Sasha Bernatsky   +7 more
doaj   +1 more source